Last reviewed · How we verify
DPT-IPV-Hib-Low（Combined Vaccine）
This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b pathogens.
This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b pathogens. Used for Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children.
At a glance
| Generic name | DPT-IPV-Hib-Low（Combined Vaccine） |
|---|---|
| Also known as | BK1310-Low |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Inactivated pentavalent vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
DPT-IPV-Hib is a pentavalent inactivated vaccine that contains antigens from five pathogens. It works by presenting these antigens to the immune system, triggering both humoral (antibody-mediated) and cell-mediated immune responses. This primes the immune system to recognize and neutralize these pathogens upon future exposure, providing protection against these five infectious diseases.
Approved indications
- Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DPT-IPV-Hib-Low（Combined Vaccine） CI brief — competitive landscape report
- DPT-IPV-Hib-Low（Combined Vaccine） updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI